MedTrace Logo

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

NCT03958721 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-11-27

No results posted yet for this study

Summary

This is a single-arm, prospective, non-randomized, feasibility study evaluating concurrent capecitabine-radiotherapy in participants with Resistant Breast Cancer.

Conditions

  • Resistant Breast Cancer
  • Non-metastatic Invasive Breast Cancer

Interventions

DRUG

Capecitabine

1,000 mg/m2 twice daily taken by mouth every other week

RADIATION

Radiotherapy

Once daily (Monday through Friday) for six weeks

Sponsors & Collaborators

  • A Bapsi Chakravarthy, MD

    lead OTHER

Principal Investigators

  • Bapsi Chakravarthy, MD · Vanderbilt Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-18
Primary Completion
2023-10-26
Completion
2023-10-26
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03958721 on ClinicalTrials.gov